Cannabis Stock, Lexaria Bioscience Corp. (LXRP), Offers Early Opportunity

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Good morning everyone. As promised in Wednesday afternoon's newsletter, today we've got a new trading idea from the cannabis space for you... sort of. While this company's biotechnology lends itself to maximizing the inherent health benefits of hemp, the science could have a sweeping impact on the nutraceutical, supplement and even drug industries as well.


The company is Lexaria Bioscience Corp. (LXRP), and as of yesterday, the bullish argument got a whole lot better.


We'll look at the news and the company in detail in a moment. The first thing we want to do is set the stage for you, just so you have a perfectly clear idea of where this story is going.

Biotricity (BTCY) Leaves No Doubt

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Was anybody really surprised the market didn't follow through on yesterday's rally effort? After all, this has pretty much been the norm since July.... the bulls can't make a firm commitment, but the bears can't either. We're still dancing right on the fence. The only difference between today and yesterday is, as of today we're facing in a bearish direction. We're still not actually moving in that direction.


We'll slice and dice it below. The first thing we want to look at today is pretty big news from featured stock Biotricity (BTCY) .


You know the company. This is the outfit that's beating Fitbit at its own game by developing a heart rate monitor that actually works. It's not just a consumer device in the works though. There's also a hospital-grade mobile cardiac-monitoring device in the works, which as we told you last week just got part of the FDA's 501k clearance. There's another part of it still pending, but that decision should be made soon.

Here's Why the NFL is Toast

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Good afternoon everyone, or good morning for those of you who don't get to read the evening newsletter until the day after it's published. Regardless of when you check it out, welcome back from the weekend, and welcome to the new trading week.


We've got a pretty close look at the market for you today... not that there's a whole lot worth talking about yet. Stocks were up, but they ended the day well off their highs and ended the day right on the fence. We're still trapped, though it's still worth a look just to get a feel for how we're trapped, and where we might break free.


We'll take a look at that in a moment. First, may I rant just a bit?

How to Survive This Go-Nowhere Market

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Today's lack of meaningful movement from stocks marks the end of the third month of stagnation. It's getting pretty old, really, but worse than that, I'm afraid it could last a while. Stocks ARE overvalued, which is keeping a lid on any breakout effort. Yet, traders are also looking to hang in there until and then after November 8th, thinking the next President might light a much-needed fire under the economy. This indecision could keep things on ice (for better or worse) well into the new year.


It's not as if your hands are completely tied though. Yes, the whole thing is quite frustrating, but we're going to look at three specific ways you can keep your portfolio's value moving ahead even when the market isn't.


We know some of you are already doing some of these things, but it's unlikely all of you are doing all of them.

Biotricity (BTCY) Gets a Crucial Green Light From the FDA

Feb 11, 2021

/

11:24 AM PST

Rating

No ratings

Good morning all. Are you sitting down, ready to do some trading? Hopefully you see this before it's too late to do anything about it, if you've been kickin' the tires on this idea.


Just a few moments ago, biotricity inc. (BTCY) -- the company we introduced to you back on July 18th to tout the potential of its mobile heart-monitoring technology -- received the FDA's 510k clearance for a key component of that device. With regulatory approval in hand, biotricity is closer to beginning the manufacturing and marketing of its bioflux device.


A 510k clearance is the equivalent to an approval of an ingestible or injectable drug. Since the testing and development pathways are different, so too is the approval process.

<<54  55  56  57  58  59  60  61  62  63  >>